Yoshiro Okubo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yoshiro Okubo has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Takeshi Sassa
Section of Psychiatry and Behavioural Science, Graduate School of Tokyo Medical and Dental University, Tokyo
3 shared publicationsTetsuya Suhara
Division of Advanced Technology for Medical Imaging, National Institute of Radiological Sciences and CREST, Japan Science and Technology Corporation, Chiba, and
3 shared publicationsYasuhiko Sudo
Division of Advanced Technology for Medical Imaging, National Institute of Radiological Sciences and CREST, Japan Science and Technology Corporation, Chiba, and
3 shared publicationsYasuhiro Someya
Section of Psychiatry and Behavioural Science, Graduate School of Tokyo Medical and Dental University, Tokyo
3 shared publicationsEisuke Matsushima
Section of Psychiatry and Behavioral Science, Department of Neurobehavioral Medicine, Division of Cognitive and Behavioral Medicine, Graduate School of Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan
2 shared publicationsKaoru Kobayashi
Division of Advanced Technology for Medical Imaging, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan
2 shared publications
Latest Publications
- Open Access
- 1 February 2001
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 55 (1) , 41-47
Ten year progressive ventricular enlargement in schizophrenia: An MRI morphometrical study
Recent studies of the brain using magnetic resonance imaging (MRI) have suggested progressive structural changes in schizophrenics. However, those studies were conducted over periods of less than 5 years and thus lacked sufficient capacity to determine the course and nature of this process. In this study, MRI scans were obtained in 15 schizophrenics and 12 controls at baseline and after 4‐ and 10‐year follow ups. Volumes of the lateral ventricles were measured. Patients were assessed by the Brief Psychiatric Rating Scale (BPRS) at the same two time points: at baseline and at 10‐year follow up. After 10 years, a significant lateral ventricular enlargement was found in patients (mean percentage change: +22.9%) but not in controls (5.1%). Although our results are not in disagreement with the neurodevelopmental hypothesis, they do provide strong evidence that in schizophrenia progressive brain reduction occurs even in its chronic stage.
- 1 February 2001
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 55 (1) , 41-47
Open AccessTen year progressive ventricular enlargement in schizophrenia: An MRI morphometrical study
Recent studies of the brain using magnetic resonance imaging (MRI) have suggested progressive structural changes in schizophrenics. However, those studies were conducted over periods of less than 5 years and thus lacked sufficient capacity to determine the course and nature of this process. In this study, MRI scans were obtained in 15 schizophrenics and 12 controls at baseline and after 4‐ and 10‐year follow ups. Volumes of the lateral ventricles were measured. Patients were assessed by the Brief Psychiatric Rating Scale (BPRS) at the same two time points: at baseline and at 10‐year follow up. After 10 years, a significant lateral ventricular enlargement was found in patients (mean percentage change: +22.9%) but not in controls (5.1%). Although our results are not in disagreement with the neurodevelopmental hypothesis, they do provide strong evidence that in schizophrenia progressive brain reduction occurs even in its chronic stage.
- 1 May 2000
- Published by Elsevier in Life Sciences
- Vol. 66 (25) , 2455-2464
Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography
- 1 May 2000
- Published by Elsevier in Life Sciences
- Vol. 66 (25) , 2455-2464
Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography
- 1 February 1997
- Published by Springer Nature in Nature
- Vol. 385 (6617) , 634-636
Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET
Schizophrenia is believed to involve altered activation of dopamine receptors, and support for this hypothesis conies from the antipsychotic effect of antagonists of the dopamine D2 receptor (D2R)1. D2R is expressed most highly in the striatum, but most of the recent positron emission tomography (PET) studies have failed to show any change in D2R densities in the striatum of schizophrenics2–5, raising the possibility that other receptors may also be involved. In particular, the dopamine D1 receptor (D1R), which is highly expressed in the prefrontal cortex6, has been implicated in the control of working memory7,8, and working memory dysfunction is a prominent feature of schizophrenia9. We have therefore used PET to examine the distribution of D1R and D2R in brains of drug-naive or drug-free schizophrenic patients. Although no differences were observed in the striatum relative to control subjects, binding of radioligand to D1R was reduced in the prefrontal cortex of schizophrenics. This reduction was related to the severity of the negative symptoms (for instance, emotional withdrawal) and to poor performance in the Wisconsin Card Sorting Test10. We propose that dysfunction of D1R signalling in the prefrontal cortex may contribute to the negative symptoms and cognitive deficits seen in schizophrenia.
- 1 February 1997
- Published by Springer Nature in Nature
- Vol. 385 (6617) , 634-636
Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET
Schizophrenia is believed to involve altered activation of dopamine receptors, and support for this hypothesis conies from the antipsychotic effect of antagonists of the dopamine D2 receptor (D2R)1. D2R is expressed most highly in the striatum, but most of the recent positron emission tomography (PET) studies have failed to show any change in D2R densities in the striatum of schizophrenics2–5, raising the possibility that other receptors may also be involved. In particular, the dopamine D1 receptor (D1R), which is highly expressed in the prefrontal cortex6, has been implicated in the control of working memory7,8, and working memory dysfunction is a prominent feature of schizophrenia9. We have therefore used PET to examine the distribution of D1R and D2R in brains of drug-naive or drug-free schizophrenic patients. Although no differences were observed in the striatum relative to control subjects, binding of radioligand to D1R was reduced in the prefrontal cortex of schizophrenics. This reduction was related to the severity of the negative symptoms (for instance, emotional withdrawal) and to poor performance in the Wisconsin Card Sorting Test10. We propose that dysfunction of D1R signalling in the prefrontal cortex may contribute to the negative symptoms and cognitive deficits seen in schizophrenia.